Jorveza (budesonide orodispersible tablets) / Dr Falk 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   10 News 
  • ||||||||||  Jorveza (budesonide orodispersible tablets) / Dr Falk
    Review, Journal:  Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence? (Pubmed Central) -  Nov 3, 2023   
    Budesonide orodispersible tablet (BOT) and budesonide oral suspension (BOS) both surpassed placebo formulations regarding the efficacy of inducing and maintaining histologic, symptomatic and endoscopic remission...Fluticasone propionate (APT-1011) achieved and maintained histologic and endoscopic responses in the majority of patients, whereas only a positive trend was demonstrated for symptomatic improvement...Current evidence supports long-term treatment with novel corticosteroid formulations, challenging the established treatment paradigm of EoE. BOT appears to be the most effective steroid therapy, although head-to-head comparative trials between STCs are needed.
  • ||||||||||  Jorveza (budesonide orodispersible tablets) / Dr Falk
    Journal, HEOR:  Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost-Utility Analysis. (Pubmed Central) -  Nov 16, 2021   
    In this large prospective trial, a 6-week open-label treatment with BOT 1 mg BID was highly effective and safe in achieving clinico-histological remission of active EoE and confirmed the results of the placebo-controlled EOS-1 trial. BOT was cost-effective compared to no treatment for both the induction and maintenance of clinico-pathological remission of EoE in patients non-responsive to PPIs.
  • ||||||||||  Jorveza (budesonide orodispersible tablets) / Dr Falk
    [VIRTUAL] EOSINOPHILIC ESOPHAGITIS – OUR CLINICAL EXPERIENCE WITH ORODISPERSIBLE TABLET FORMULATION BUDESONIDE (BOT) (Poster Exhibition) -  Jul 20, 2021 - Abstract #UEGW2021UEGW_4139;    
    Optimal timing with regards to treatment escalation requires further evaluation but our data suggest that prior TS use is not associated with a difference in response rates with BOT. Prospective analysis with clinical-histological and endoscopic assessment is superior but currently challenging due to the COVID-19 pandemic.
  • ||||||||||  Jorveza (budesonide orodispersible tablets) / Dr Falk
    [VIRTUAL] EOSINOPHILIC ESOPHAGITIS – OUR CLINICAL EXPERIENCE WITH ORODISPERSIBLE TABLET FORMULATION BUDESONIDE (BOT) (Poster Exhibition) -  Jul 20, 2021 - Abstract #UEGW2021UEGW_1959;    
    Optimal timing with regards to treatment escalation requires further evaluation but our data suggest that prior TS use is not associated with a difference in response rates with BOT. Prospective analysis with clinical-histological and endoscopic assessment is superior but currently challenging due to the COVID-19 pandemic.
  • ||||||||||  Jorveza (budesonide orodispersible tablets) / Dr Falk
    Review, Journal:  Treatment of eosinophlic esophagitis with swallowed topical corticosteroids. (Pubmed Central) -  May 15, 2021   
    Whereas it was shown that disease remission induction of EoE by STCs is highly effective, there is still a lack of data regarding long-term and maintenance therapy. However, current studies on STC maintenance therapy add some movement into the game.
  • ||||||||||  budesonide / Generic mfg., Budenofalk (budesonide effervescent tablet) / Dr Falk
    Journal:  EMERGING THERAPIES FOR EOSINOPHILIC ESOPHAGITIS. (Pubmed Central) -  Jul 29, 2020   
    Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article, we will discuss recent advances in EoE treatment with regards to swallowed topical steroids, biological agents, dietary approaches and novel molecular targets.
  • ||||||||||  budesonide / Generic mfg., Budenofalk (budesonide effervescent tablet) / Dr Falk
    Review, Journal:  Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. (Pubmed Central) -  Jun 23, 2020   
    The new orodispersible budesonide tablet with effervescent properties is the first approved esophageal-targeted formulation specifically developed for the treatment of EoE, which has become available in many European countries. This article gives an overview of the evolution of topical corticosteroids in EoE and provides an update on recent data from large-scale multicenter trials exploring the efficacy and safety of the orodispersible budesonide tablet with effervescent properties in adult EoE patients.
  • ||||||||||  Jorveza (budesonide orodispersible tablets) / Dr Falk
    Enrollment closed, Trial completion date:  EOS-2: Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis (clinicaltrials.gov) -  Feb 12, 2019   
    P3,  N=204, Active, not recruiting, 
    This article gives an overview of the evolution of topical corticosteroids in EoE and provides an update on recent data from large-scale multicenter trials exploring the efficacy and safety of the orodispersible budesonide tablet with effervescent properties in adult EoE patients. Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Dec 2020
  • ||||||||||  Jorveza (budesonide orodispersible tablets) / Dr Falk
    Enrollment open, Trial initiation date, Trial primary completion date:  EOS-1: Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis (clinicaltrials.gov) -  Jan 21, 2016   
    P3,  N=90, Recruiting, 
    Initiation date: Aug 2015 --> Feb 2016 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Nov 2015 | Trial primary completion date: Mar 2017 --> Sep 2017